SGLT-2 inhibitors and CV protection: Transforming the landscape of T2DM management
02 Oct 2018
The third front – ‘Control’ – seeks to adopt better disease management to prevent or delay complications and ensure a good quality of life at all stages.
Type 2 diabetes mellitus (T2DM) is associated with substantial risks of cardiovascular disease (CVD) risk and overall mortality, despite the advances in treatment options.1 Recently, MIMS Doctor spoke to Dato’ Sri Dr Azhari Rosman, a Senior Consultant Cardiologist at the National Heart Institute, to provide an update on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in managing CV risk associated with T2DM, and discuss the results of the recently published Comparative Effectiveness of Cardiovascular Outcomes (CVD-REAL) 2 study. Here are the highlights from the interview.
Related MIMS Drugs